Cell and Gene Therapy and Connected Health

This Is Greater Philadelphia’s Moment | Key Messages

Explore key messages and supporting factoids about the Greater Philadelphia Region’s leadership in Cell and Gene Therapy and Connected Health in this one-sheet document.

Cell and Gene Therapy and Connected Health Toolkit

The Cell and Gene Therapy and Connected Health Tool Kit is a living resource centered on the Greater Philadelphia region’s past, present and future as a hub for cell and gene therapy and connected health.

Research

Beyond Cellicon Valley

Recent headlines have celebrated the first FDA approved gene therapy and CAR-T cell immune-oncology treatments, born in academic institutions based here in Philadelphia.

Why the Country’s Top Biotech Companies are Flocking to Philadelphia

The leaders behind some of the most successful biotech companies in the country have chosen to grow their businesses in Philadelphia because, even when compared to Silicon Valley, Philadelphia has the most to offer, they say.

Results

ExpressCells Announces First Close of Series A Financing

Philadelphia-based ExpressCells, Inc. (ExpressCells), a private genetic engineering company that creates advanced cell lines for drug discovery, announced that it has completed the first close of its Series A financing round, lead jointly this round by The Rowan Innovation Venture Fund and Keiretsu Forum Mid-Atlantic.

Gene Therapy With Research Origins In Greater Philadelphia Approved By FDA to Treat Spinal Muscular Atrophy

Dr. James Wilson and his team at Penn Medicine are celebrating the U.S. Food and Drug Administration (FDA) of a gene therapy known as Zolgensma for Spinal Muscular Atrophy, based on a delivery vehicle that his team discovered and developed over the past decade as part of a wide-ranging portfolio of research to advance gene therapy.

Momentum

New South Philadelphia Offices Planned for California-based Iovance

Cancer-therapy firm Iovance Biotherapeutics Inc. plans to open a sprawling office and laboratory complex in South Philadelphia’s Navy Yard complex, adding to the city’s growing clout as a biotechnology research-and-development hub.

Roche Agrees to buy Spark Therapeutics for $4.3 billion